drugset / Trial / NCT05034952

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

NCT05034952

Phase 2 Completed 303 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.

Timeline

Start
2021-08-30
Primary completion
2021-12-05
Completion
2021-12-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 325 mg Oral
Subject Suzetrigine Small molecule 30 mg Oral
Subject Suzetrigine Small molecule 50 mg Oral
Comparator hydrocodone bitartrate Unknown 5 mg Oral

Indications

No indication recorded.